65,437 trials
Breast Cancer
Primary: The Frequencies of Paired Responses to Identical Questions on a Survey Administered at Two Timepoints: Before the Health Education Program (i.e., Baseline) and…
Stroke
Primary: Total Intervention Time — 966; 680 Minutes — p=.182
Malaria
Primary: Number of Participants With at Least One Adverse Events of Specific Interest (AESI) From Month 0 to Month 79 — 12; 11; 16 Participants
Non Hodgkin Lymphoma · Follicular Lymphoma · Indolent Lymphoma
Primary: Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year — 5 Participants
Alcoholic Hepatitis
Primary: Number of Subjects With Clinical Data Collected — 717; 257; 159 Participants
Schizophrenia · Traumatic Brain Injury
Primary: Mismatch Negativity (MMN) Amplitudes in Microvolts — -0.59; -1.19; -0.41; -0.65 microvolts
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Epidermolysis Bullosa
Primary: Event-free Survival — 4; 2; 1 Count of Participants
Asthma · Chronic Obstructive Pulmonary Disease (COPD) · Congestive Heart Failure
Primary: Preventable Emergency Department (ED) Admissions — 0.038; 0.048 count of ED admissions per person per q — p=0.0793
Caregiver Burnout
Primary: Caregiver Burden Score at Month 3 and Month 9 — 23.73; 25.56; 21.41; 27.67 units on a scale
Agitation Associated With Dementia of the Alzheimer's Type
Primary: The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 90.2; 90.3 Percentage of percipitante
Primary Progressive Aphasia
Primary: Percentage of Participants Who Complete 16 Out of 20 Study Visits — 100 percentage of participants
Chronic Pain
Primary: System Usability Scale (SUS) — 79.6 score on a scale
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
Post-Schizophrenic Depression
Primary: Calgary Depression Scale for Schizophrenia (CDSS) — 8.31; 8.62 score on a scale